CA
NZ
UK
AU
IND
US
• 60 Degrees Pharmaceuticals received a favorable safety recommendation from an independent Data Safety Monitoring Board for its B-FREE study.
• $100 Million Offering Priced at $20: The public offering was priced at $20.00 per share, with gross proceeds intended to fund three pipeline programs simultaneously.
• $21 Million Raised at Steep Discount: The private placement was priced at $5.91 per share, a significant discount to the market price, with a healthcare-focused investor as the counterparty.
• FDA Type B Meeting Requested: OS Therapies is seeking to harmonize OST-HER2 trial endpoints with international standards ahead of a 2026 data readout.
• 43% First-Cycle Complete Remission Rate: The Annamycin plus HiDAC combination achieved 43% and 36% first-cycle complete remission rates versus 12% in the HiDAC monotherapy control arm.
• No ARIA-E Observed at 12 Months: The 12-month ABATE interim data showed a favorable safety profile with no observed Amyloid-Related Imaging Abnormalities — Edema, a key safety concern in Alzheimer's immunotherapy.
• FDA CRL Cites Manufacturing Only: The Complete Response Letter identified unresolved issues at a third-party manufacturing facility with no concerns raised about clinical data or safety.
• Primary Endpoint Not Met: Fasedienol showed an LS mean SUDS change of -9.5 versus -11.4 for placebo, a statistically insignificant result with p=0.427.
• 37.2% of Non-Responders Achieved Remission: Patients who failed induction had a 37.2% clinical remission rate in the ABTECT Maintenance Part 2 study, a meaningful result for a refractory population.
• Reports indicate KKR and Sixth Street Partners have agreed to a $1 billion preferred equity financing.
Please wait processing your request...